B Lynne Parshall Sells 5,000 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Director B Lynne Parshall sold 5,000 shares of Ionis Pharmaceuticals stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $82.72, for a total value of $413,600.00. Following the completion of the transaction, the director owned 56,344 shares in the company, valued at approximately $4,660,775.68. The trade was a 8.15% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Ionis Pharmaceuticals Price Performance

Shares of IONS stock opened at $80.60 on Friday. The business has a fifty day simple moving average of $80.70 and a 200 day simple moving average of $69.31. The company has a market cap of $13.05 billion, a P/E ratio of -47.69 and a beta of 0.29. The company has a quick ratio of 2.78, a current ratio of 2.79 and a debt-to-equity ratio of 0.96. Ionis Pharmaceuticals, Inc. has a twelve month low of $23.95 and a twelve month high of $86.74.

Analysts Set New Price Targets

IONS has been the topic of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a report on Thursday, January 22nd. Leerink Partners boosted their target price on shares of Ionis Pharmaceuticals from $85.00 to $100.00 and gave the stock an “outperform” rating in a research note on Monday, December 15th. TD Cowen reiterated a “buy” rating on shares of Ionis Pharmaceuticals in a report on Wednesday, December 3rd. Barclays assumed coverage on Ionis Pharmaceuticals in a report on Wednesday, January 28th. They set an “overweight” rating and a $95.00 price objective on the stock. Finally, Needham & Company LLC boosted their price objective on Ionis Pharmaceuticals from $78.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Ionis Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $86.95.

Institutional Trading of Ionis Pharmaceuticals

Several institutional investors have recently modified their holdings of IONS. Brown Brothers Harriman & Co. acquired a new position in Ionis Pharmaceuticals during the 4th quarter worth about $27,000. Golden State Wealth Management LLC raised its position in shares of Ionis Pharmaceuticals by 198.4% during the third quarter. Golden State Wealth Management LLC now owns 376 shares of the company’s stock worth $25,000 after acquiring an additional 250 shares during the last quarter. Steigerwald Gordon & Koch Inc. acquired a new position in shares of Ionis Pharmaceuticals in the third quarter worth approximately $25,000. Mather Group LLC. acquired a new position in shares of Ionis Pharmaceuticals in the third quarter worth approximately $27,000. Finally, Quarry LP bought a new stake in Ionis Pharmaceuticals in the third quarter valued at approximately $38,000. Institutional investors own 93.86% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.